The information was released late on Tuesday by the health information website Stat News and later confirmed by the pharmaceutical company itself, in a statement sent to the North American television channel CNN.
“As part of the ongoing controlled and randomized global trials of the Oxford coronavirus vaccine, our standard review process has triggered a pause in vaccination to allow review of safety data,” the company said in a statement.
AstraZeneca stressed that it is “a routine action, which should happen whenever there is a potentially unexplained illness in one of the trials, while it is being investigated”, in order to ensure that “the integrity of the trials” is maintained.
“In large-scale tests, diseases happen by chance, but they must be independently reviewed in order to be carefully checked. We are working to accelerate the review of a single event to minimize any potential impact on the test schedule. We are committed to the safety of our participants and the highest standards of conduct in our tests, “concluded the statement.
Thus, studies on the final stage of the vaccine are suspended while the company investigates whether a report from a patient with a serious side effect is related to the product under development.
An AstraZeneca spokesman confirmed that the vaccination break covers testing in the United States of America (USA) and other countries.
–
/data/photo/2020/09/08/5f573bf208b8c.jpg?resize=150%2C150&ssl=1)
